Highland Therapeutics, a Toronto, Canada-based pharmaceutical company, closed a $25m in funding.
The backer was was an unnamed private equity investor.
The company intends to use the funds, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc. to complete the clinical development of HLD-200 through to a New Drug Application, conduct a Phase IIB/III study of HLD-100 (amphetamine), expand manufacturing capacity and pursue pipeline expansion opportunities.
Led by David Lickrish, President & Chief Executive Officer, Highland is developing HLD-200 (methylphenidate), which is being investigated in an ongoing Phase III clinical trial entitled Clinical Endpoint Evaluation Study, or CEES, for the treatment of symptoms associated with ADHD.
FinSMEs
16/10/2014